FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282947054> ?p ?o ?g. }

• W4282947054 endingPage "179" @default.
• W4282947054 startingPage "171" @default.
• W4282947054 abstract "The incretin hormone system is the target of multiple type 2 diabetes mellitus (T2DM) treatments because defects in this system play major roles in the pathogenesis of diabetes. Currently, the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are recommended for patients with atherosclerotic cardiovascular (CV) disease and those at high risk for atherosclerotic CV disease. In addition to the favorable CV effects, GLP-1 RAs also provide robust lowering of hemoglobin A1c and weight. Although these factors make GLP-1 RAs attractive options for T2DM, the currently available agents have no effect on glucose-dependent insulinotropic polypeptide (GIP). Patients with T2DM are known to have GIP defect which is significant due to its profound insulinotropic effects. Tirzepatide is a novel incretin agent currently recently approved by the Food and Drug Administration for the treatment of T2DM. This first-in-class agent serves as a coagonist for both the GLP-1 and GIP receptors. In this review, we report on the pharmacologic mechanism of GLP-1, GIP, and coagonist effects on the cardiometabolic system. In addition, we review the glycemic lowering, weight loss effects, and other cardiometabolic outcomes of tirzepatide based on phase 2 and 3 data. The safety profile of tirzepatide is consistent across all phase 3 trials. The most common adverse effects are gastrointestinal symptoms, but they generally have a low risk for discontinuation. Overall, preliminary data suggest that tirzepatide is an efficacious and safe agent for the treatment of T2DM." @default.
• W4282947054 created "2022-06-16" @default.
• W4282947054 creator A5014755813 @default.
• W4282947054 creator A5020833178 @default.
• W4282947054 creator A5023756886 @default.
• W4282947054 creator A5028628945 @default.
• W4282947054 creator A5048899271 @default.
• W4282947054 date "2022-08-01" @default.
• W4282947054 modified "2023-10-03" @default.
• W4282947054 title "A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health" @default.
• W4282947054 cites W2080103614 @default.
• W4282947054 cites W2098730220 @default.
• W4282947054 cites W2215535790 @default.
• W4282947054 cites W2261184724 @default.
• W4282947054 cites W2425644022 @default.
• W4282947054 cites W2804558913 @default.
• W4282947054 cites W2887185538 @default.
• W4282947054 cites W2895135221 @default.
• W4282947054 cites W2895666357 @default.
• W4282947054 cites W2948612418 @default.
• W4282947054 cites W3004172664 @default.
• W4282947054 cites W3011482816 @default.
• W4282947054 cites W3047536039 @default.
• W4282947054 cites W3087889571 @default.
• W4282947054 cites W3102426258 @default.
• W4282947054 cites W3110873848 @default.
• W4282947054 cites W3127371223 @default.
• W4282947054 cites W3133746780 @default.
• W4282947054 cites W3141710292 @default.
• W4282947054 cites W3177122952 @default.
• W4282947054 cites W3177393241 @default.
• W4282947054 cites W3183842190 @default.
• W4282947054 cites W3191712049 @default.
• W4282947054 cites W3205201678 @default.
• W4282947054 cites W4210940103 @default.
• W4282947054 cites W4212978690 @default.
• W4282947054 cites W4213427170 @default.
• W4282947054 doi "https://doi.org/10.1097/fjc.0000000000001299" @default.
• W4282947054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35767712" @default.
• W4282947054 hasPublicationYear "2022" @default.
• W4282947054 type Work @default.
• W4282947054 citedByCount "3" @default.
• W4282947054 countsByYear W42829470542023 @default.
• W4282947054 crossrefType "journal-article" @default.
• W4282947054 hasAuthorship W4282947054A5014755813 @default.
• W4282947054 hasAuthorship W4282947054A5020833178 @default.
• W4282947054 hasAuthorship W4282947054A5023756886 @default.
• W4282947054 hasAuthorship W4282947054A5028628945 @default.
• W4282947054 hasAuthorship W4282947054A5048899271 @default.
• W4282947054 hasConcept C126322002 @default.
• W4282947054 hasConcept C134018914 @default.
• W4282947054 hasConcept C197934379 @default.
• W4282947054 hasConcept C2777180221 @default.
• W4282947054 hasConcept C2778715236 @default.
• W4282947054 hasConcept C2778881409 @default.
• W4282947054 hasConcept C2780473172 @default.
• W4282947054 hasConcept C2780533449 @default.
• W4282947054 hasConcept C2910068830 @default.
• W4282947054 hasConcept C555293320 @default.
• W4282947054 hasConcept C71924100 @default.
• W4282947054 hasConcept C98274493 @default.
• W4282947054 hasConceptScore W4282947054C126322002 @default.
• W4282947054 hasConceptScore W4282947054C134018914 @default.
• W4282947054 hasConceptScore W4282947054C197934379 @default.
• W4282947054 hasConceptScore W4282947054C2777180221 @default.
• W4282947054 hasConceptScore W4282947054C2778715236 @default.
• W4282947054 hasConceptScore W4282947054C2778881409 @default.
• W4282947054 hasConceptScore W4282947054C2780473172 @default.
• W4282947054 hasConceptScore W4282947054C2780533449 @default.
• W4282947054 hasConceptScore W4282947054C2910068830 @default.
• W4282947054 hasConceptScore W4282947054C555293320 @default.
• W4282947054 hasConceptScore W4282947054C71924100 @default.
• W4282947054 hasConceptScore W4282947054C98274493 @default.
• W4282947054 hasIssue "2" @default.
• W4282947054 hasLocation W42829470541 @default.
• W4282947054 hasLocation W42829470542 @default.
• W4282947054 hasOpenAccess W4282947054 @default.
• W4282947054 hasPrimaryLocation W42829470541 @default.
• W4282947054 hasRelatedWork W1676753054 @default.
• W4282947054 hasRelatedWork W1945989183 @default.
• W4282947054 hasRelatedWork W2100816243 @default.
• W4282947054 hasRelatedWork W2161407981 @default.
• W4282947054 hasRelatedWork W2411384485 @default.
• W4282947054 hasRelatedWork W2918860281 @default.
• W4282947054 hasRelatedWork W4361286763 @default.
• W4282947054 hasRelatedWork W2189420872 @default.
• W4282947054 hasRelatedWork W2492475437 @default.
• W4282947054 hasRelatedWork W2610552735 @default.
• W4282947054 hasVolume "80" @default.
• W4282947054 isParatext "false" @default.
• W4282947054 isRetracted "false" @default.
• W4282947054 workType "article" @default.